WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) said it has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care.
The company said the newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.
Boston Scientific noted that the X4 line of quadripolar CRT-Ds offers 70 percent more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the largest battery capacity in the industry. These newly approved devices continue the Boston Scientific history of industry-leading projected longevity and a six-year CRT-D warranty.
Extending the Boston Scientific portfolio of defibrillators, the ICDs in the MINI family are the world's smallest and thinnest devices and are designed for patient comfort.
ICDs and CRT-Ds are designed to treat patients suffering from heart failure and/or to provide protection to patients at risk of sudden cardiac death.
Copyright RTT News/dpa-AFX
© 2014 AFX News
